Dianthus Therapeutics

DNTH · Nasdaq · United States

Share price · DNTH

$83.98-31.56 (-27.32%) 3M

close as of 2026-11-18 · 24h delayed · vol 862K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when DNTH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Jul 2026+8.2%
  2. 17 Jul 2026+10.7%

    Nothing announced by DNTH that day or the session before.

  3. 1 Jul 2026-7.5%

    Nothing announced by DNTH that day or the session before.

  4. 12 Jun 2026+7.4%

    Nothing announced by DNTH that day or the session before.

  5. 10 Jun 2026-9.6%

    Nothing announced by DNTH that day or the session before.

  6. 10 Mar 2026+9.7%

    Nothing announced by DNTH that day or the session before.

  7. 9 Mar 2026+21.5%
  8. 4 Mar 2026+12.0%

    Nothing announced by DNTH that day or the session before.

  9. 22 Jan 2026+9.8%

    Nothing announced by DNTH that day or the session before.

  10. 13 Jan 2026+14.7%

    Nothing announced by DNTH that day or the session before.

Share of unusual movement by asset

For each asset, the share of DNTH's own-move activity since 17 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
LBL-047
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—1%
Sessions with no dated event—99%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
BDCA2 (CLEC4C) / TACIProtein / enzyme therapeutic
Systemic Lupus Erythematosus

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$46M$56M+ $782M short-term inv.$47M-$50M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$49M$111M+ $776M short-term inv.$50M-$49M operating cash flowreport ↗
2026-Q1—$35M$628M+ $484M short-term inv.$41M-$29M operating cash flowreport ↗
2025-Q3$0.4M$32M$56M+ $347M short-term inv.$37M-$31M operating cash flowreport ↗
2025-Q2$0.2M$26M$13M+ $244M short-term inv.$32M-$24M operating cash flowreport ↗
2025-Q1$1.2M$27M$10M+ $253M short-term inv.$30M-$28M operating cash flowreport ↗
2024-Q3$2.2M$26M$34M+ $247M short-term inv.$25M-$21M operating cash flowreport ↗
2024-Q2$1.9M$18M$314M+ $47M short-term inv.$18M-$15M operating cash flowreport ↗
2024-Q1$0.9M$13M$330M+ $47M short-term inv.$14M-$15M operating cash flowreport ↗
2023-Q3$0.9M$8.0M$157M+ $33M short-term inv.$15M$17M operating cash flowreport ↗
2023-Q2—$0.1M$63M+ $15M short-term inv.$3.3M-$6.5M operating cash flowreport ↗
2023-Q1—$8.0M$50M+ $30M short-term inv.$29M-$36M operating cash flowreport ↗
2022-Q3$1.2M$11M$61M+ $69M short-term inv.$16M-$14M operating cash flowreport ↗
2022-Q2—$12M$57M+ $85M short-term inv.$17M-$17M operating cash flowreport ↗
2022-Q1—$17M$74M+ $85M short-term inv.$23M-$20M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.0M$146M$51M+ $353M short-term inv.$41M-$129M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$6.2M$83M$23M+ $252M short-term inv.$21M-$78M operating cash flowreport ↗
2023-FY$2.8M$33M$132M+ $41M short-term inv.$11M-$37M operating cash flowreport ↗
2022-FY$6.4M$55M$59M+ $60M short-term inv.$19M-$67M operating cash flowreport ↗
2021-FY$1.5M$47M$133M+ $0 short-term inv.$18M-$60M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 71 sales ($75.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12Savitz Ryan · EVP, CFO & CBOOption exercise1,339$21.77$29KForm 4
2026-11-12Savitz Ryan · EVP, CFO & CBOOption exercise16,385$22.07$362KForm 4
2026-11-12Savitz Ryan · EVP, CFO & CBOOpen-market sale17,724$90.56$1.6MForm 4
2026-11-12Savitz Ryan · EVP, CFO & CBOOption exercise (derivative)1,339——Form 4
2026-11-12Savitz Ryan · EVP, CFO & CBOOption exercise (derivative)16,385——Form 4
2026-11-11Savitz Ryan · EVP, CFO & CBOOption exercise1,744$21.77$38KForm 4
2026-11-11Savitz Ryan · EVP, CFO & CBOOption exercise1,300$22.07$29KForm 4
2026-11-11Savitz Ryan · EVP, CFO & CBOOpen-market sale3,044$90.03$274KForm 4